Close

Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Impressive Q4 and Guidance

January 27, 2012 10:10 AM EST
Get Alerts CPHD Hot Sheet
Price: $52.95 --0%

Rating Summary:
    11 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Cepheid (NASDAQ: CPHD) price target raised from $45 to $50.00.

Analyst, Jeffrey Frelick, said, "Showing no signs of economic fatigue: Record instrument placements (88 US, 87 OUS) displayed geographical balance as GeneXpert continues to consolidate competing platforms. Europe grew 30% in Q4, while HBDC added 181 systems...2012 outlook positive. Established strong revenue guidance of $333-347M (up 20-25%). GAAP EPS guided to $0.17-0.24 (non-GAAP $0.55-0.60) as R&D and G&A increase, as well as share count. Management usually guides conservatively."

For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $34.35 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments